Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Im getting a Seafood Tower 3 feet tall !!!!!!!!!!!!!!!!!
Pains of rapid growth can be managed.
Catalyst check off:
X 1. Cash Flow Positive Status - 5 years
X 2. Purchase building housing their cGMP registered facility for research, development, manufacturing and packaging of pharmaceutical products.
X 3. Adderall IR $335 Million Approved and Launched
X 4. Adderall XR $1.56 Billion Approved and Launched
X 5. Double digit quarterly revenues in millions
X 6. In house marketing and distribution: Kirko Kirkov, Doug Plassche and their teams
X 7. Prasco/Burel Adderall agreement starting January 1st 2024
X 8. First shipment Adderall XR to PRASCO Dec 2023
X 9. DEA increases manufacturing quotas for Adderall & Vyvance
X 10. Generic Vyvanse - $5.1 BILLION - FDA submission Dec 2023
X 11. FDA Acceptance of Generic OxyContin Sept 2023
__12. Dopamine Agonist (probably Requip XL or Mirapex ER). $12 Million
X 13. Vigabatrin Approval $233 Million
__14. Pyros Settle Vigabatrin -VigPoder trade mark challenge then Launch
__15. Generic Methotrexate Approval- Antimetabolite $42 Million
__16. $50 million in yearly revenues
X 17. Lease additional manufacturing space and storage vault for new Needle Mover ANDAs - Jan 2024
X 18. PE ratio below 8
__19. Generate revenues over $20 million/quarter
__20. Generic OxyContin Approval - FIRST TO FILE Aug 17, 2023 $720 Million
__21. Prevail over Purdue in Generic OxyContin infringement suit - 6 month stay
__22. Legislation to make manufacturing generic drugs more profitable
__23. European distribution - Dexcel partnership approval by Israeli Health
__24. Full ownership of Adderall IR $ 335 Million
__25. Full ownership of Adderall XR $ 1.56 Billion
__26. Generic Concerta- $1.2 BILLION FDA submission
__27. $100 million in yearly revenue
__28. Generic Vyvanse Approval and Launch
__29. $200 million in yearly revenue
__30. Deep pocket partner for SequestOx
__31. Patented Unique ADF (w/o naltrexone)-- NDA
__32. Mikah ANDA (s)
__33. Undisclosed ANDAs/NDAs
__34. DollarLand PPS
__35. Uplist to the NASDAQ Exchange
__36. ELTP Elite Pharmaceutical Buyout - less than 2 1/2 years from Feb 2024
__37. Vegas Baby !!!!!!!
I can only do $10-15 K a week
Not sure how many shares more I need ?
I’m ready for next Bear Raid , you ?
Emperor and I are ready to step on if it comes to it.
Bear Raids will be addressed.
ELTP
great for adding 50K mord
Whats amazing is you watching this go from 2 cents to 21 cents.
50 K a week till CC
BuyA Thon is starting.
GLTY
I Filled that gap Twice now
$$$
Need room for $5.1 Billion Vyvance
$720 million OxyContin
and one more NeedleMover
$5.1 Billion
Turn it into $1000 to $2000
GLTY
catalyst:
X 1. Cash Flow Positive Status - 5 years
X 2. Purchase building housing their cGMP registered facility for research, development, manufacturing and packaging of pharmaceutical products.
X 3. Adderall IR $335 Million Approved and Launched
X 4. Adderall XR $1.56 Billion Approved and Launched
X 5. Double digit quarterly revenues in millions
X 6. In house marketing and distribution: Kirko Kirkov, Doug Plassche and their teams
X 7. Prasco/Burel Adderall agreement starting January 1st 2024
X 8. First shipment Adderall XR to PRASCO Dec 2023
X 9. DEA increases manufacturing quotas for Adderall & Vyvance
X 10. Generic Vyvanse - $5.1 BILLION - FDA submission Dec 2023
X 11. FDA Acceptance of Generic OxyContin Sept 2023
__12. Dopamine Agonist (probably Requip XL or Mirapex ER). $12 Million
X 13. Vigabatrin Approval $233 Million
X 14. Pyros Settle Vigabatrin -VigPoder trade mark challenge then LAUNCH
__15. Generic Methotrexate Approval- Antimetabolite $42 Million
__16. $50 million in yearly revenues
X 17. Lease additional manufacturing space and storage vault for new Needle Mover ANDAs - Jan 2024
__18. Generate revenues over $20 million/quarter
__19. Generic OxyContin Approval - FIRST TO FILE Aug 17, 2023 $720 Million
__20. Prevail over Purdue in Generic OxyContin infringement suit - 6 month stay
__21. European distribution - Dexcel partnership approval by Israeli Health
__22. Full ownership of Adderall IR $ 335 Million
__23. Full ownership of Adderall XR $ 1.56 Billion
__24. Generic Concerta- $1.2 BILLION FDA submission
__25. $100 million in yearly revenue
__26. Generic Vyvanse Approval and Launch
__27. $200 million in yearly revenue
__28. Deep pocket partner for SequestOx
__29. Patented Unique ADF (w/o naltrexone)-- NDA
__30. Mikah ANDA (s)
__31. Undisclosed ANDAs/NDAs
__32. DollarLand PPS
__33. Uplist to the NASDAQ Exchange
__34. ELTP Elite Pharmaceutical Buyout - less than 2 1/2 years from Feb 2024
__35. Vegas Baby !!!!!!!
X 36. PE below 8.
I have the winning ticket for 22 months from now.
Im taking advantage of any dips
$$$$$$$$$$$$$$$$$$$$$$
Massive BuyOut 22 months
GLTA
Welcome back !
I’m going out to celebrate what We have here.
Enjoy the calm before the CC.
GLTA
The goat boiler room can’t bring anything to the table.
They are backed up against a wall by this:
X 1. Cash Flow Positive Status - 5 years
X 2. Purchase building housing their cGMP registered facility for research, development, manufacturing and packaging of pharmaceutical products.
X 3. Adderall IR $335 Million Approved and Launched
X 4. Adderall XR $1.56 Billion Approved and Launched
X 5. Double digit quarterly revenues in millions
X 6. In house marketing and distribution: Kirko Kirkov, Doug Plassche and their teams
X 7. Prasco/Burel Adderall agreement starting January 1st 2024
X 8. First shipment Adderall XR to PRASCO Dec 2023
X 9. DEA increases manufacturing quotas for Adderall & Vyvance
X 10. Generic Vyvanse - $5.1 BILLION - FDA submission Dec 2023
X 11. FDA Acceptance of Generic OxyContin Sept 2023
__12. Dopamine Agonist (probably Requip XL or Mirapex ER). $12 Million
X 13. Vigabatrin Approval $233 Million
X 14. Pyros Settle Vigabatrin -VigPoder trade mark challenge then LAUNCH
__15. Generic Methotrexate Approval- Antimetabolite $42 Million
__16. $50 million in yearly revenues
X 17. Lease additional manufacturing space and storage vault for new Needle Mover ANDAs - Jan 2024
__18. Generate revenues over $20 million/quarter
__19. Generic OxyContin Approval - FIRST TO FILE Aug 17, 2023 $720 Million
__20. Prevail over Purdue in Generic OxyContin infringement suit - 6 month stay
__21. European distribution - Dexcel partnership approval by Israeli Health
__22. Full ownership of Adderall IR $ 335 Million
__23. Full ownership of Adderall XR $ 1.56 Billion
__24. Generic Concerta- $1.2 BILLION FDA submission
__25. $100 million in yearly revenue
__26. Generic Vyvanse Approval and Launch
__27. $200 million in yearly revenue
__28. Deep pocket partner for SequestOx
__29. Patented Unique ADF (w/o naltrexone)-- NDA
__30. Mikah ANDA (s)
__31. Undisclosed ANDAs/NDAs
__32. DollarLand PPS
__33. Uplist to the NASDAQ Exchange
__34. ELTP Elite Pharmaceutical Buyout - less than 2 1/2 years from Feb 2024
__35. Vegas Baby !!!!!!!
X 36. PE below 8.
We got to get Nasrat paid for all those shares he has.
Is there any other way to liquidate them?
An extra penny won’t matter much to me a buyout.
Good Luck
I will be buying where ever we are, till next CC.
We will see who does the best at BuyOut
At least I did not cry and whine from $0.97 to $0.02 and up to $0.15.
ELTP Locked $$ Loaded
$5.1 Billion Market drug approval end of year. Approx buyout in 22 months.
New facility will be ready To Rock and Roll !!!!!!!!!!!!!
Im feelin' it !!
ELTP
Glad I did not listen to you at 2 cents.
Feed That Goat
NEWS AmeraMex International GAAP EPS of -$0.05, revenue of $13.38M
15% = $1,500,000,000 Kirkov is the WildCard
Its about To Get Real !!!!!!!!!!!! Between now and the next CC.
ELTP
Elite will be first to market Generic OxyContin
$720 MILLION Market
This will blow this stock upward.
Locked and Loaded not chasing
GLTA
$10 bILLION combined IMS markets.
5% = $$ 500,000,000
7.5% = $$$$750,000,000
10% = $$$$$$1,000,000,000
More to come:
X 1. Cash Flow Positive Status - 5 years
X 2. Purchase building housing their cGMP registered facility for research, development, manufacturing and packaging of pharmaceutical products.
X 3. Adderall IR $335 Million Approved and Launched
X 4. Adderall XR $1.56 Billion Approved and Launched
X 5. Double digit quarterly revenues in millions
X 6. In house marketing and distribution: Kirko Kirkov, Doug Plassche and their teams
X 7. Prasco/Burel Adderall agreement starting January 1st 2024
X 8. First shipment Adderall XR to PRASCO Dec 2023
X 9. DEA increases manufacturing quotas for Adderall & Vyvance
X 10. Generic Vyvanse - $5.1 BILLION - FDA submission Dec 2023
X 11. FDA Acceptance of Generic OxyContin Sept 2023
__12. Dopamine Agonist (probably Requip XL or Mirapex ER). $12 Million
X 13. Vigabatrin Approval $233 Million
X 14. Pyros Settle Vigabatrin -VigPoder trade mark challenge then LAUNCH
__15. Generic Methotrexate Approval- Antimetabolite $42 Million
__16. $50 million in yearly revenues
X 17. Lease additional manufacturing space and storage vault for new Needle Mover ANDAs - Jan 2024
__18. Generate revenues over $20 million/quarter
__19. Generic OxyContin Approval - FIRST TO FILE Aug 17, 2023 $720 Million
__20. Prevail over Purdue in Generic OxyContin infringement suit - 6 month stay
__21. European distribution - Dexcel partnership approval by Israeli Health
__22. Full ownership of Adderall IR $ 335 Million
__23. Full ownership of Adderall XR $ 1.56 Billion
__24. Generic Concerta- $1.2 BILLION FDA submission
__25. $100 million in yearly revenue
__26. Generic Vyvanse Approval and Launch
__27. $200 million in yearly revenue
__28. Deep pocket partner for SequestOx
__29. Patented Unique ADF (w/o naltrexone)-- NDA
__30. Mikah ANDA (s)
__31. Undisclosed ANDAs/NDAs
__32. DollarLand PPS
__33. Uplist to the NASDAQ Exchange
__34. ELTP Elite Pharmaceutical Buyout - less than 2 1/2 years from Feb 2024
__35. Vegas Baby !!!!!!!
X 36. PE below 8.
I took on a few more. Still have $$ to buy more and more coming soon.
Locked $ Loaded
ELTP
What position do you play on the MB ?
SQUEEEEEEE !!!!!
yOU GOT SPOOFED AT 2 CENTS A SHARE
and will be doinging it at 50 cents too, lmao
yOU SAID THAT AT 2 CENTS TOO, lol
Shortages:
FDA shortage link
for Adderall:
https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Amphetamine%20Aspartate%20Monohydrate,%20Amphetamine%20Sulfate,%20Dextroamphetamine%20Saccharate,%20Dextroamphetamine%20Sulfate%20Tablet&st=c&tab=tabs-1
FDA shortage link for Vyvance
https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Lisdexamfetamine%20Dimesylate%20Capsule&st=c
FDA shortage link for Concerta
https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Methylphenidate%20Hydrochloride%20Tablet,%20Extended%20Release&st=c
FDA shortage link for Naltrexone
https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Naltrexone%20Hydrochloride%20Tablet&st=c
FDA shortage link for Methotrexate
https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Methotrexate%20Sodium%20Tablet&st=c
Bullish
Looking good going forward:
X 1. Cash Flow Positive Status - 5 years
X 2. Purchase building housing their cGMP registered facility for research, development, manufacturing and packaging of pharmaceutical products.
X 3. Adderall IR $335 Million Approved and Launched
X 4. Adderall XR $1.56 Billion Approved and Launched
X 5. Double digit quarterly revenues in millions
X 6. In house marketing and distribution: Kirko Kirkov, Doug Plassche and their teams
X 7. Prasco/Burel Adderall agreement starting January 1st 2024
X 8. First shipment Adderall XR to PRASCO Dec 2023
X 9. DEA increases manufacturing quotas for Adderall & Vyvance
X 10. Generic Vyvanse - $5.1 BILLION - FDA submission Dec 2023
X 11. FDA Acceptance of Generic OxyContin Sept 2023
__12. Dopamine Agonist (probably Requip XL or Mirapex ER). $12 Million
X 13. Vigabatrin Approval $233 Million
X 14. Pyros Settle Vigabatrin -VigPoder trade mark challenge then Launch
__15. Generic Methotrexate Approval- Antimetabolite $42 Million
__16. $50 million in yearly revenues
X 17. Lease additional manufacturing space and storage vault for new Needle Mover ANDAs - Jan 2024
X 18. PE ratio below 8
__19. Generate revenues over $20 million/quarter
__20. Generic OxyContin Approval - FIRST TO FILE Aug 17, 2023 $720 Million
__21. Prevail over Purdue in Generic OxyContin infringement suit - 6 month stay
__22. Legislation to make manufacturing generic drugs more profitable
__23. European distribution - Dexcel partnership approval by Israeli Health
__24. Full ownership of Adderall IR $ 335 Million
__25. Full ownership of Adderall XR $ 1.56 Billion
__26. Generic Concerta- $1.2 BILLION FDA submission
__27. $100 million in yearly revenue
__28. Generic Vyvanse Approval and Launch
__29. $200 million in yearly revenue
__30. Deep pocket partner for SequestOx
__31. Patented Unique ADF (w/o naltrexone)-- NDA
__32. Mikah ANDA (s)
__33. Undisclosed ANDAs/NDAs
__34. DollarLand PPS
__35. Uplist to the NASDAQ Exchange
__36. ELTP Elite Pharmaceutical Buyout - less than 2 1/2 years from Feb 2024
__37. Vegas Baby !!!!!!!
I was going to ask you if you had any goat.
Stay safe.
What are we worth at $80 million/ yr revenues?
What are we worth at $100 million/yr run rate ?
We in the HammerZone now.
GLTA
$10 Billion combined IMS markets:
Catalyst check off:
X 1. Cash Flow Positive Status - 5 years
X 2. Purchase building housing their cGMP registered facility for research, development, manufacturing and packaging of pharmaceutical products.
X 3. Adderall IR $335 Million Approved and Launched
X 4. Adderall XR $1.56 Billion Approved and Launched
X 5. Double digit quarterly revenues in millions
X 6. In house marketing and distribution: Kirko Kirkov, Doug Plassche and their teams
X 7. Prasco/Burel Adderall agreement starting January 1st 2024
X 8. First shipment Adderall XR to PRASCO Dec 2023
X 9. DEA increases manufacturing quotas for Adderall & Vyvance
X 10. Generic Vyvanse - $5.1 BILLION - FDA submission Dec 2023
X 11. FDA Acceptance of Generic OxyContin Sept 2023
__12. Dopamine Agonist (probably Requip XL or Mirapex ER). $12 Million
X 13. Vigabatrin Approval $233 Million
X 14. Pyros Settle Vigabatrin -VigPoder trade mark challenge then Launch
__15. Generic Methotrexate Approval- Antimetabolite $42 Million
__16. $50 million in yearly revenues
X 17. Lease additional manufacturing space and storage vault for new Needle Mover ANDAs - Jan 2024
X 18. PE ratio below 8
__19. Generate revenues over $20 million/quarter
__20. Generic OxyContin Approval - FIRST TO FILE Aug 17, 2023 $720 Million
__21. Prevail over Purdue in Generic OxyContin infringement suit - 6 month stay
__22. Legislation to make manufacturing generic drugs more profitable
__23. European distribution - Dexcel partnership approval by Israeli Health
__24. Full ownership of Adderall IR $ 335 Million
__25. Full ownership of Adderall XR $ 1.56 Billion
__26. Generic Concerta- $1.2 BILLION FDA submission
__27. $100 million in yearly revenue
__28. Generic Vyvanse Approval and Launch
__29. $200 million in yearly revenue
__30. Deep pocket partner for SequestOx
__31. Patented Unique ADF (w/o naltrexone)-- NDA
__32. Mikah ANDA (s)
__33. Undisclosed ANDAs/NDAs
__34. DollarLand PPS
__35. Uplist to the NASDAQ Exchange
__36. ELTP Elite Pharmaceutical Buyout - less than 2 1/2 years from Feb 2024
__37. Vegas Baby !!!!!!!